Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 14-17 January 2019
 
Share
News 18/01/2019
At its monthly meeting, EMA’s safety committee () carried out its broad range of responsibilities, which cover all aspects of the risk management of the use of medicines: assessment of , ,  and post-authorisation safety studies.
The Committee did not start or conclude any  procedures. More information on all safety reviews currently under evaluation is provided in the ‘Ongoing ’ table.
Information on all topics discussed by the  is available in the agenda below. A record of the discussions held this week will be provided in the minutes of this meeting, which will be published following the next 

PRACmeeting in February.
